Samuel Suzuki

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

J.F.R. Robertson, Jean-­Marc Ferrero, Hugues Bourgeois et al. · The Lancet Oncology · 2013 · 166 citations

Medicine, Oncology, Pharmacology +16

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Paul M. Barr, Jennifer Brown, Peter Hillmen et al. · Blood · 2017 · 143 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

Allen Lee Cohn, Josep Tabernero, Joan Maurel et al. · Annals of Oncology · 2013 · 89 citations · Full text

Medicine, Oncology, Pharmacology +14

Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor

Ian McCaffery, Yanyan Tudor, Hongjie Deng et al. · Clinical Cancer Research · 2013 · 66 citations

Medicine, Oncology, Pharmacology +17

Abstract S1-4: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC)

PA Kaufman, J-M Ferrero, Hugues Bourgeois et al. · Cancer Research · 2010 · 45 citations

Medicine, Endocrinology, Oncology +16